Omeros Published Study In "Blood Advances" Shows Narsoplimab Significantly Improves Survival In High-Risk TA-TMA Patients

Omeros Corporation (NASDAQ:OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology,detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for marketing approval by both the U.S. FDA and the European Medicines Agency.

Authored by an international panel of transplant experts, the manuscript – titled "Survival in Adults with High Risk TA-TMA—A Comparative Analysis of Narsoplimab Versus Supportive Care" – reports significant, multifold reductions in mortality risk across pivotal trial and EAP patient cohorts, individually and pooled, treated with narsoplimab compared to a well-matched external control group who did not receive narsoplimab. Consistent with previous narsoplimab clinical studies, no safety signals of concern were observed. The full manuscript is available online.